Lain L Lee
Nurse Practitioner · Santa Clara
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 4
- 1 carrier
- Office
- 1
- Since medical school
- 7 years
- Graduated 2019
Offices
1 location · Permanente Medical Group Inc · 10,928 clinicians in this group
Looking this up.
Plans that list them
4 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Lain L Lee’s office at (408) 851-1000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Kaiser Permanente Dual Complete North P2 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Dual Complete North P23 (HMO D-SNP) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Basic Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
| Kaiser Permanente Sr Adv Enhanced Santa Clara (HMO) | Kaiser Permanente | Listed | Sep 1, 2026 |
Drugs they prescribed that Part D paid
$548,747
Pharmacies billed $548,747 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
222 generic and 33 brand-name prescriptions · $548,747 in drug cost · 18 antibiotic prescriptions to 13 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenalidomide | 35 | $377,962 | $10,799 |
| Acyclovir | 20 | $341 | $17 |
Year by year
| 2024 | 255 | 96 | None | 13% | $548,747 |
| 2023 | 746 | 199 | 6% (42) | 29% | $2,468,700 |
| 2022 | 797 | 227 | 8% (67) | 26% | $2,237,048 |
| 2021 | 267 | 127 | 11% (29) | 38% | $348,326 |
| 2020 | 82 | 30 | 0% (0) | 34% | $11,695 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 22 drugs
| Revlimid | 29 | $434,784 | $14,993 |
| Ibrance | 18 | $295,818 | $16,434 |
| Imbruvica | 18 | $285,299 | $15,850 |
| Tasigna | 19 | $277,497 | $14,605 |
| Xtandi | 14 | $189,336 | $13,524 |
| Promacta | 12 | $99,178 | $8,265 |
| Imatinib Mesylate | 22 | $81,804 | $3,718 |
| Orgovyx | 25 | $65,613 | $2,625 |
| Eliquis | 30 | $19,980 | $666 |
| Anastrozole | 97 | $5,379 | $55 |
| Exemestane | 12 | $2,936 | $245 |
| Letrozole | 47 | $1,773 | $38 |
| Hydroxyurea | 17 | $682 | $40 |
| Ondansetron | 19 | $458 | $24 |
| Hydrocodone-Acetaminophen | 20 | $427 | $21 |
| Levothyroxine | 29 | $387 | $13 |
| Loperamide | 21 | $356 | $17 |
| Alendronate | 28 | $217 | $8 |
| Dexamethasone | 23 | $143 | $6 |
| Prednisone | 16 | $121 | $8 |
| Prochlorperazine Maleate | 11 | $117 | $11 |
| Tramadol | 12 | $55 | $5 |
2022: 20 drugs
| Revlimid | 27 | $475,902 | $17,626 |
| Ibrance | 22 | $313,503 | $14,250 |
| Tasigna | 11 | $179,210 | $16,292 |
| Promacta | 12 | $69,917 | $5,826 |
| Imatinib Mesylate | 21 | $25,291 | $1,204 |
| Eliquis | 35 | $23,114 | $660 |
| Exemestane | 21 | $7,609 | $362 |
| Anastrozole | 135 | $5,487 | $41 |
| Letrozole | 40 | $1,179 | $29 |
| Hydroxyurea | 28 | $964 | $34 |
| Hydrocodone-Acetaminophen | 31 | $877 | $28 |
| Tamoxifen Citrate | 12 | $833 | $69 |
| Ondansetron | 26 | $558 | $21 |
| Levothyroxine | 30 | $493 | $16 |
| Dexamethasone | 26 | $463 | $18 |
| Gabapentin | 15 | $326 | $22 |
| Loperamide | 17 | $244 | $14 |
| Alendronate | 33 | $205 | $6 |
| Prednisone | 17 | $143 | $8 |
| Tramadol | 19 | $86 | $5 |
2021: 3 drugs
| Prosol | 46 | $12,439 | $270 |
| Anastrozole | 24 | $1,063 | $44 |
| Hydrocodone-Acetaminophen | 20 | $539 | $27 |
2020: 1 drug
| Prosol | 23 | $6,292 | $274 |
Money from drug and device companies
$54 in 2025
| 2025 | 1 | 2 | None | $54 |
| 2024 | 2 | 2 | None | $53 |
| 2023 | 33 | 97 | None | $2,521 |
| 2022 | 38 | 210 | None | $3,843 |
| 2021 | 30 | 79 | None | $1,809 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbvie | Epkinly | $54 | 2 payments
|
See all 2 published payments
| Abbvie | Meals · 2025-07-22 | Epkinly | $24 |
| Abbvie | Meals · 2025-03-25 | Epkinly | $30 |
See earlier years (2024, 2023, 2022, 2021)
2024: $53
| Abbvie | Epkinly | $30 | 1 payment
|
| Novartis Pharmaceuticals | Fabhalta | $24 | 1 payment
|
2023: $2,521
| Novartis Pharmaceuticals | Kisqali | $281 | 11 payments
|
| Exelixis | Cabometyx | $204 | 4 payments
|
| Celgene | Pomalyst | $182 | 7 payments
|
| Pfizer | Bosulif | $180 | 11 payments
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $166 | 5 payments
|
| Incyte | Jakafi | $158 | 6 payments
|
| Seagen | Tukysa | $152 | 3 payments
|
| Janssen Biotech | Imbruvica | $108 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $98 | 4 payments
|
| Astellas Pharma US | Padcev | $88 | 2 payments
|
| Bayer Healthcare Pharmaceuticals | Stivarga | $88 | 4 payments
|
| Merck Sharp & Dohme | Keytruda | $77 | 3 payments
|
| GlaxoSmithKline | Zejula | $76 | 4 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $61 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $58 | 2 payments
|
| BeiGene USA | Brukinsa | $55 | 2 payments
|
| Eisai | Lenvima | $53 | 2 payments
|
| Daiichi Sankyo | Enhertu | $52 | 2 payments
|
| Genmab U.S. | Epkinly | $42 | 2 payments
|
| Rigel Pharmaceuticals | Rezlidhia | $39 | 2 payments
|
| Sobi | Doptelet | $39 | 2 payments
|
| Gilead Sciences | Trodelvy | $30 | 1 payment
|
| Puma Biotechnology | None | $30 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Epkinly | $29 | 1 payment
|
| PharmaEssentia USA | Besremi | $24 | 1 payment
|
| Amgen | Lumakras | $24 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $23 | 1 payment
|
| Stemline Therapeutics | Orserdu | $22 | 1 payment
|
| Foundation Medicine | Foundationone Liquid Cdx | $21 | 1 payment
|
| Deciphera Pharmaceuticals | Qinlock | $19 | 1 payment
|
| Agios Pharmaceuticals | Pyrukynd | $19 | 1 payment
|
| Novocure | Optune | $14 | 1 payment
|
| Lilly USA | Verzenio | $13 | 1 payment
|
2022: $3,843
| Novartis Pharmaceuticals | Kisqali | $360 | 19 payments
|
| Eisai | Lenvima | $302 | 10 payments
|
| Pfizer | Inlyta | $280 | 21 payments
|
| Janssen Biotech | Darzalex | $232 | 9 payments
|
| Merck Sharp & Dohme | Keytruda | $203 | 10 payments
|
| Bayer HealthCare Pharmaceuticals | Nubeqa | $201 | 6 payments
|
| Gilead Sciences | Trodelvy | $148 | 7 payments
|
| Amgen | Nplate | $147 | 6 payments
|
| Astellas Pharma US | Padcev | $144 | 6 payments
|
| Genzyme | Enjaymo | $139 | 7 payments
|
| Takeda Pharmaceuticals U.S.A. | Alunbrig | $134 | 3 payments
|
| Incyte | Monjuvi | $132 | 5 payments
|
| Celgene | Pomalyst | $123 | 6 payments
|
| Karyopharm Therapeutics | Xpovio | $111 | 4 payments
|
| Seagen | Tukysa | $110 | 5 payments
|
| Pharmacyclics LLC an AbbVie | Imbruvica | $105 | 4 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $100 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Enhertu | $99 | 5 payments
|
| Exelixis | Cabometyx | $95 | 3 payments
|
| Lilly USA | Verzenio | $85 | 5 payments
|
| Sobi | Doptelet | $74 | 4 payments
|
| Daiichi Sankyo | Enhertu | $64 | 3 payments
|
| Puma Biotechnology | Nerlynx | $56 | 3 payments
|
| Taiho Oncology | Lonsurf | $44 | 2 payments
|
| BeiGene USA | Brukinsa | $41 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $41 | 2 payments
|
| EUSA Pharma (US) | Sylvant | $32 | 2 payments
|
| GlaxoSmithKline | Zejula | $32 | 2 payments
|
| Adaptive Biotechnologies | Clonoseq | $27 | 1 payment
|
| Jazz Pharmaceuticals | Zepzelca | $24 | 1 payment
|
| Servier Pharmaceuticals | Tibsovo | $23 | 1 payment
|
| MorphoSys US | Monjuvi | $23 | 1 payment
|
| G1 Therapeutics | Cosela | $22 | 1 payment
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $20 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $19 | 1 payment
|
| Acrotech Biopharma | Beleodaq | $18 | 1 payment
|
| AVEO Pharmaceuticals | Fotivda | $18 | 1 payment
|
| Novocure | Optune | $17 | 1 payment
|
2021: $1,809
| Astellas Pharma US | Xospata | $327 | 6 payments
|
| Incyte | Jakafi | $220 | 8 payments
|
| Pfizer | Inlyta | $199 | 15 payments
|
| Novartis Pharmaceuticals | Lutathera | $89 | 5 payments
|
| Rigel Pharmaceuticals | Tavalisse | $83 | 2 payments
|
| Amgen | Lumakras | $81 | 3 payments
|
| Karyopharm Therapeutics | Xpovio | $81 | 4 payments
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $78 | 3 payments
|
| Boehringer Ingelheim Pharmaceuticals | Gilotrif | $69 | 3 payments
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $58 | 3 payments
|
| Ipsen Biopharmaceuticals | Somatuline Depot | $46 | 2 payments
|
| Eisai | Lenvima | $43 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $42 | 2 payments
|
| Janssen Biotech | Darzalex | $37 | 2 payments
|
| Servier Pharmaceuticals | Tibsovo | $37 | 2 payments
|
| Exelixis | Cabometyx | $31 | 1 payment
|
| Bayer HealthCare Pharmaceuticals | Stivarga | $30 | 2 payments
|
| EMD Serono | None | $27 | 2 payments
|
| Lilly USA | Verzenio | $24 | 1 payment
|
| Daiichi Sankyo | Enhertu | $22 | 1 payment
|
| Celgene | Abecma | $22 | 1 payment
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $22 | 1 payment
|
| Ge Healthcare | None | $20 | 1 payment
|
| Seagen | None | $20 | 1 payment
|
| EUSA Pharma (US) | Sylvant | $20 | 1 payment
|
| Gilead Sciences | Trodelvy | $18 | 1 payment
|
| TOLMAR Pharmaceuticals | Eligard | $18 | 1 payment
|
| Taiho Oncology | Lonsurf | $16 | 1 payment
|
| Dova Pharmaceuticals | Doptelet | $15 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Exkivity | $13 | 1 payment
|
Professional record
- NPI
- 1538780218
- Licence
- CA NP95014078
- Gender
- Female
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 954430908, CA GR0052990
- Taxonomy
- Federal specialty code 363LF0000X (363LF0000X)
- Mailing address
- 18000 Studebaker Rd Ste 800, Cerritos, CA, 90703
- NPI first listed
- 2020-05-04
- NPI last updated
- 2021-03-10
- NPI record certified
- 2021-03-10
This is when the NPI record was last certified, not a medical board exam.